BEIJING, Oct. 19 /PRNewswire-Asia/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products, today announced that the Company has received approval for its SPR-based analysis system (the "SPR System") from the State Food and Drug Administration of China (the "SFDA").
The SPR System utilizes Surface Plasmon Resonance ("SPR") technology, a leading biosensor technology in molecular biology. SPR technology has been successfully used for the analysis of proteins, nucleic acids and viruses for the past 20 years and has become a powerful platform for life sciences, drug discovery, medicine and food safety. Human papillomavirus ("HPV"), a common virus that infects the skin and mucous membranes of humans and causes various kinds of warts as well as cervical cancer, can be detected by adding pathological samples on the HPV-DNA biosensor chip (the "HPV-DNA chip") and analyzing the HPV-DNA chip with the SPR System. The SPR System is label-free with high throughput, high speed and a high degree of automation. The detection results can be displayed on a real-time and online basis. The SPR System can be used in various potential clinical diagnostic applications, such as the detection of biomarkers related to infectious diseases, cancers, cardiovascular disorders and immune system disorders.
"We are pleased to receive the SFDA approval for our SPR System on a timely basis," commented Mr. Xiaodong Wu, Chairman and Chief Executive Officer of the Company. "We have commenced the delivery of our SPR Systems to our large hospital customers and believe that more and more women will benefit from the use of our SPR system and HPV-DNA chips together with our cervical cancer FISH probes, both of which can guide physicians to determine and apply effective treatment in the early stages of cervical diseases to reduce the risk of cervical cancer as well as early detection of cervical cancer."
About China Medical Technologies, Inc.
China Medical Technologies is a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic (IVD) products using Enhanced Chemiluminescence (ECLIA) technology, Fluorescent in situ Hybridization (FISH) technology and Surface Plasmon Resonance (SPR) technology to detect and monitor various diseases and disorders. For more information, please visit http://www.chinameditech.com .
Safe Harbor Statement
This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in the Company's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.
For more information, please contact:
Winnie Yam
Tel: +852-2511-9808
Email: IR@chinameditech.com
